CVRx, Inc. (CVRX) Q3 2024 Financial Results

CVRx, Inc. (CVRX) reported a 27% increase in total revenue for Q3 2024, reaching $13.4 million, largely driven by its US Heart Failure business.

Despite a solid revenue performance, the company experienced a net loss of $13.1 million, or $0.57 per share. CVRx announced significant reimbursement achievements that are expected to improve patient access and payment processes for its Barostim therapy.

Company Outlook

• 2024 Revenue Projection: Total revenue expected to be between $50.5 million and $51.5 million.
• Q4 Revenue Projection: Anticipated to be between $14.5 million and $15.5 million.
• Gross Margin Expectations: Between 83% and 85% for the full year.

Key Takeaways

• Q3 2024 revenue increased by 27% YoY to $13.4 million.
• Net loss was $13.1 million (compared to a loss of $9 million in Q3 2023).
• Significant reimbursement achievements include higher DRG payments and Category 1 CPT code approval for Barostim therapy.
• US Heart Failure revenue reached $12.2 million from 391 units.
• European revenues grew by 15% to $1.1 million.
• Gross profit for the quarter was $11.1 million, showcasing an 83% gross margin.
• Cash and cash equivalents were $100.2 million, with operating expenses projected around $100 million for the full year.

Bullish and Bearish Highlights

Bullish

• Strengthened balance sheet with a $20 million loan drawdown and a $20.3 million equity offering.
• Optimism about reaching cash flow breakeven and sustaining mid- to high 20% growth rates.
• New sales strategies expected to enhance productivity and retention.

Bearish

• Net loss widened from $9 million in Q3 2023 to $13.1 million in Q3 2024.
• Administrative expenses rose by 38% due to higher compensation and operational costs.

InvestingPro Insights

• Revenue increase aligns with key metrics; 27% growth in Q3 2024 reflects a 43.94% growth over the last twelve months.
• While strong revenue is notable, CVRx remains unprofitable with an operating loss of $55.39 million.
• Strong cash position indicates a good balance with cash exceeding debt.

Conclusion

CVRx is focusing on expanding market penetration for Barostim therapy with recent reimbursement successes and strategic sales initiatives to make it a standard care option for heart failure.

Full Transcript Highlights

CEO Kevin Hykes presented notable revenue achievements and strategic goals during the Q3 2024 earnings call, emphasizing the transformative potential of Barostim therapy while outlining progress toward increased patient access and support through improved reimbursements. The leadership team has been instrumental in these efforts, focusing on education, clinical evidence, and market adoption.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.